Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodomethane SCHEMBL17005795 | 0.94 | ALDH1A1 (0.57) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1147702 | 0.84 | KDM4E (0.73) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4508472 | 0.84 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1422257 | 0.83 | CES2 (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL11223392 | 0.83 | CES2 (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL28727383 | 0.83 | CES2 (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL674215 | 0.82 | HDAC2 (0.62) | TLR7HDAC6HDAC2HDAC8SMN1; SMN2 | |
| SCHEMBL23723198 | 0.81 | CES2 (0.59) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL162189 | 0.81 | ALDH1A1 (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4754862 | 0.81 | CES2 (0.59) | CES2CES1LMNAL3MBTL1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011632-A1 | HYDROXIMIC ACID COMPOUNDS CONTAINING TETRAHYDROBENZO[4,5]FURANO[2,3-C]PYRIDINE, PREPARATION METHOD THEREFOR, AND USES THEREOF | 浙江大学 | 2025-01-16 | — | — | WO | claimed |
| CN-117088891-A | Tetrahydrobenzo [4,5] furan [2,3-C ] pyridine hydroxamic acid compound and preparation method and application thereof | 浙江大学 | 2023-11-21 | — | — | CN | claimed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | claimed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | claimed |
| EP-1003751-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999006410-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-02-11 | — | — | WO | claimed |
| EP-0060144-A2 | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | claimed |
| JP-57120597-A | — | — | None | — | — | JP | disclosed |
| JP-5201964-A | — | — | None | — | — | JP | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| WO-1993015044-A1 | N-BENZYLOXAMIC ACID, OXAMATE, AND OXAMIDE DERIVATIVES AND THEIR USE AS TNF AND PDE IV INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-08-05 | — | — | WO | disclosed |
| EP-0065039-B1 | AN O-(N-ALKOXY-PYRIDINECARBOXIMIDOYL)PHOSPHATE, A PROCESS FOR PRODUCING THE SAME, AND AN INSECTICIDAL OR ACARICIDAL COMPOSITION CONTAINING THE SAME | ISHIHARA SANGYO KAISHA LTD. (JP) | 1984-08-22 | — | — | EP | disclosed |
| EP-0065039-A1 | An O-(N-alkoxy-pyridinecarboximidoyl)phosphate, a process for producing the same, and an insecticidal or acaricidal composition containing the same | ISHIHARA SANGYO KAISHA LTD. (JP) | 1982-11-24 | — | — | EP | disclosed |
| EP-0060144-A2 | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
| JP-S57120597-A | ORGANOPHOSPHORUS COMPOUND AND INSECTICIDE CONTAINING THE SAME | ISHIHARA SANGYO KAISHA LTD | 1982-07-27 | — | — | JP | disclosed |
| US-4336253-A | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
| US-4327089-A | O-(N-Alkoxy-pyridinecarboximidoyl) phosphates, process for producing the same, and insecticidal or acaridical compositions containing the same | ISHIHARA SANGYO KAISHA LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | CES2 3852/4885CES1 3063/4885LMNA 2868/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | CES2 4582/4885CES1 3502/4885LMNA 3630/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | CES2 4627/4885CES1 3155/4885LMNA 2092/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CES2 4735/4885CES1 4448/4885LMNA 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.